Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Levosulpiride (RV 12309; RV-12309; S-(-)-Sulpiride) is the S-enantiomer of sulpiride, which is a potent and selective antagonist for D2 dopamine receptors used as an antipsychotic and prokinetic agent. Levosulpiride is an antipsychotic that is a substituted benzamide and is known to selectively block dopamine D2 receptor activity in both the central and peripheral nervous systems. It functions as both a prokinetic and an atypical neuroleptic. There are also claims that levosulpiride improves mood.
Targets |
D2 receptor
|
---|---|
References |
Wikipedia
|
Molecular Formula |
C15H23N3O4S
|
|
---|---|---|
Molecular Weight |
341.43
|
|
Exact Mass |
341.14
|
|
Elemental Analysis |
C, 52.77; H, 6.79; N, 12.31; O, 18.74; S, 9.39
|
|
CAS # |
23672-07-3
|
|
Related CAS # |
Levosulpiride-d3; 124020-27-5
|
|
Appearance |
Solid powder
|
|
SMILES |
CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
|
|
InChi Key |
BGRJTUBHPOOWDU-NSHDSACASA-N
|
|
InChi Code |
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
|
|
Chemical Name |
N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.9289 mL | 14.6443 mL | 29.2886 mL | |
5 mM | 0.5858 mL | 2.9289 mL | 5.8577 mL | |
10 mM | 0.2929 mL | 1.4644 mL | 2.9289 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00422175 | Completed | Drug: BAF 312 | Healthy | Novartis | October 2006 | Phase 1 |
NCT02481583 | Completed | Drug: Levosulpiride | Dyspepsia | Wuhan Union Hospital, China | July 2013 | Phase 1 |
NCT00866645 | Completed | Drug: Intramuscular Haloperidol Drug: Intramuscular Levosulpiride |
Agitation | Shanghai Mental Health Center | February 2009 | Phase 2 Phase 3 |